28.10.2021 STRATEC SE  DE000STRA555

DGAP-Adhoc: STRATEC REPORTS PRELIMINARY FIGURES FOR FIRST NINE MONTHS OF 2021 AND RAISES FINANCIAL GUIDANCE


 

DGAP-Ad-hoc: STRATEC SE / Key word(s): Preliminary Results/Change in Forecast
STRATEC REPORTS PRELIMINARY FIGURES FOR FIRST NINE MONTHS OF 2021 AND RAISES FINANCIAL GUIDANCE

28-Oct-2021 / 14:57 CET/CEST
Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.


STRATEC REPORTS PRELIMINARY FIGURES FOR FIRST NINE MONTHS OF 2021 AND RAISES FINANCIAL GUIDANCE

Birkenfeld, October 28, 2021

Based on preliminary figures, STRATEC can report further record sales and earnings for the first nine months of 2021. According to these figures, STRATEC expects consolidated sales of € 225.4 million for the first nine months of 2021, up from € 179.1 million in the previous year. On a constant-currency basis, this corresponds to organic growth of 29.5% (nominal: +25.9%). The sales performance in the third quarter of 2021 (constant currency: +16.7%) once again exceeded the budget scenario, which was most recently adjusted upwards in July 2021. Highly dynamic developments were shown by, among others, the service parts and consumables business, as well as by molecular diagnostics and immunohematology systems.

Adjusted EBIT for the first nine months of 2021 is expected to rise by 73.7% to € 48.8 million (previous year: € 28.1 million). This corresponds to an adjusted EBIT margin of 21.6% (previous year: 15.7%). The company's profitability was positively influenced in particular by benefits of scale, as well as by the sales and product mix, which exceeded recent expectations.

Based on this above-budget performance in the third quarter of 2021, and given current order volumes and updated risk adjustments, the company's Board of Management has decided once again to raise the financial guidance for the 2021 financial year. As a result, STRATEC now expects to generate constant-currency sales growth of at least 16.0% in the 2021 financial year (previously: "at least 12.0%"). For its adjusted EBIT margin, the company is forecasting a figure of around 19.0% to 20.0% (previously: "around 17.5% to 18.5%").

In view of the COVID-19 pandemic, STRATEC continues to observe increased volatility in its customers' order behavior. Global supply chains also remain tense and subject to uncertainties. The above guidance therefore specifically includes risk discounts for both sales and product mixes in the fourth quarter of 2021, as well as for potential further increases in logistics costs.

STRATEC will publish its Quarterly Statement with complete figures for the first nine months of 2021 as planned on November 11, 2021. Furthermore, a conference call (in English) will also be held on November 11, 2021.

FURTHER INFORMATION IS AVAILABLE FROM:
STRATEC SE
Jan Keppeler | Investor Relations & Corporate Communications
Tel: +49 7082 7916-6515
[email protected]
www.stratec.com


28-Oct-2021 CET/CEST The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de


Language: English
Company: STRATEC SE
Gewerbestr. 37
75217 Birkenfeld
Germany
Phone: +49 (0)7082 7916 0
Fax: +49 (0)7082 7916 999
E-mail: [email protected]
Internet: www.stratec.com
ISIN: DE000STRA555
WKN: STRA55
Indices: SDAX
Listed: Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange
EQS News ID: 1244430

 
End of Announcement DGAP News Service

1244430  28-Oct-2021 CET/CEST

fncls.ssp?fn=show_t_gif&application_id=1244430&application_name=news&site_id=boersengefluester_html


Die wichtigsten Finanzdaten auf einen Blick
  2017 2018 2019 2020 2021 2022 2023e
Umsatzerlöse1 209,76 187,82 214,16 250,10 287,34 274,63 261,91
EBITDA1,2 47,33 35,53 35,60 56,27 66,43 58,07 40,08
EBITDA-Marge3 22,56 18,92 16,62 22,50 23,12 21,14
EBIT1,4 28,84 15,01 17,19 33,68 48,18 41,14 22,39
EBIT-Marge5 13,75 7,99 8,03 13,47 16,77 14,98 8,55
Jahresüberschuss1 25,64 8,97 14,41 25,18 39,96 29,22 13,07
Netto-Marge6 12,22 4,78 6,73 10,07 13,91 10,64 4,99
Cashflow1,7 29,98 11,95 21,26 31,85 63,47 10,28 19,43
Ergebnis je Aktie8 2,22 0,75 1,20 2,07 3,28 2,41 1,07
Dividende8 0,80 0,82 0,84 0,90 0,95 0,97 0,77
Quelle: boersengefluester.de und Firmenangaben

  Geschäftsbericht 2023 - Kostenfrei herunterladen.  
1 in Mio. Euro; 2 EBITDA = Ergebnis vor Zinsen, Steuern und Abschreibungen; 3 EBITDA in Relation zum Umsatz; 4 EBIT = Ergebnis vor Zinsen und Steuern; 5 EBIT in Relation zum Umsatz; 6 Jahresüberschuss (-fehlbetrag) in Relation zum Umsatz; 7 Cashflow aus der gewöhnlichen Geschäftstätigkeit; 8 in Euro; Quelle: boersengefluester.de

Wirtschaftsprüfer: RSM Ebner Stolz

INVESTOR-INFORMATIONEN
©boersengefluester.de
Stratec
WKN Kurs in € Einschätzung Börsenwert in Mio. €
STRA55 41,400 Halten 503,33
KGV 2025e KGV 10Y-Ø BGFL-Ratio Shiller-KGV
24,35 34,72 0,68 23,42
KBV KCV KUV EV/EBITDA
2,22 25,91 1,92 15,61
Dividende '22 in € Dividende '23e in € Div.-Rendite '23e
in %
Hauptversammlung
0,97 0,55 1,33 17.05.2024
Q1-Zahlen Q2-Zahlen Q3-Zahlen Bilanz-PK
26.04.2024 09.08.2024 25.10.2024 28.03.2024
Abstand 60Tage-Linie Abstand 200Tage-Linie Performance YtD Performance 52 Wochen
-1,51% -6,46% -9,11% -33,97%
    
Weitere Ad-hoc und Unternehmensrelevante Mitteilungen zu STRATEC SE  ISIN: DE000STRA555 können Sie bei EQS abrufen


Medtech , STRA55 , SBS , XETR:SBS